Evotec
Rafael Schaeffer is an experienced finance professional currently serving as Vice President and Head of Global Treasury at Evotec since February 2024. Previously, Rafael held the position of Director and Head of Group Treasury & Financing at Pro Gamers Group from January 2023 to January 2024 and served as Head of Group Treasury at Razor Group, where foundational treasury functions, banking strategies, and risk management strategies were implemented. Rafael's tenure at Atotech Group as Treasury Manager involved developing treasury guidelines and enhancing cash management processes following a corporate carve-out. Prior experience includes roles at EY as a Senior Consultant in Capital & Debt Advisory, focusing on financing advisory and corporate finance, as well as internships in corporate finance and treasury at Merck KGaA and a banking traineeship at Deutsche Bank. Rafael holds a Bachelor of Business Administration from the University of Applied Science Wildau and a qualification as a banker from Deutsche Bank AG.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.